Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $21.3 million.

  • Axsome Therapeutics' Cash from Financing Activities fell 30.05% to $21.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.3 million, marking a year-over-year increase of 127.84%. This contributed to the annual value of $57.8 million for FY2024, which is 82.53% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Cash from Financing Activities is $21.3 million, which was down 38.43% from $34.5 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Cash from Financing Activities peaked at $246.1 million during Q2 2023, and registered a low of -$1.2 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $29.3 million (2025), whereas its average is $43.1 million.
  • Within the past 5 years, the most significant YoY rise in Axsome Therapeutics' Cash from Financing Activities was 712,300.00% (2024), while the steepest drop was 102.30% (2024).
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Cash from Financing Activities stood at $1.1 million in 2022, then tumbled by 100.19% to -$2,000 in 2023, then soared by 712,300.00% to $14.2 million in 2024, then tumbled by 30.05% to $21.3 million in 2025.
  • Its Cash from Financing Activities was $21.3 million in Q3 2025, compared to $34.5 million in Q2 2025 and $29.3 million in Q1 2025.